Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price shot up 10.3% during trading on Monday . The stock traded as high as $3.95 and last traded at $3.95, with a volume of 63,041 shares trading hands. The stock had previously closed at $3.58.

Several research firms recently commented on ABEO. Rodman & Renshaw reissued a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a report on Friday, August 5th. Zacks Investment Research lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, June 1st. Maxim Group reissued a “buy” rating and issued a $6.00 target price on shares of Abeona Therapeutics in a report on Tuesday, August 2nd. Finally, FBR & Co reissued a “buy” rating on shares of Abeona Therapeutics in a report on Wednesday, June 22nd.

The company’s market capitalization is $128.23 million. The stock’s 50-day moving average is $2.78 and its 200-day moving average is $2.70.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. Analysts forecast that Abeona Therapeutics Inc. will post ($0.66) EPS for the current fiscal year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC increased its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.